Empire Med Group Announces Historically High Q3 2026 Revenue
Diversified portfolio supports continued leadership across all markets served
Q3 2026 Performance
Empire Med Group achieved historically high revenue in Q3 2026, driven by the strength and diversity of its product portfolio. The company continues to lead across every geographic market it serves, reinforcing its position for sustained growth as 2026 draws to a close.
Looking Ahead
“Empire Med Group is backed by a strong corporate structure and an exceptional sales and support team at the account level. With the strategies we have adopted and the new tools we are providing, we are confident that sustained double-digit sales growth will continue in 2027. Additional product introductions and geographic expansion into new markets, including the Midwest, will help drive that growth.”
Keith Sheaffer
President, Empire Med Group
